N/A N=62 Phlebotomy to Prevent Blood Loss in Major Hepatic Resections
Liver Neoplasms · Hepatectomy
Primary: Total Intraoperative Blood Loss, by Measurement of Change in Hemoglobin Levels — 862; 872; 761; 872 mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=70 Fibrin Sealant VH S/D 500 S-apr in Hepatic Resection
Bleeding (Oozing) in Hepatic Resection
Primary: Percentage of Participants With Intraoperative Hemostasis at 4 Minutes After Treatment Application — 82.9; 37.1 percentage of participants — p=<0.001
Phase 3 N=253 TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery
Hemorrhage
Primary: Percentage of Participants With Intraoperative Hemostasis at Target Bleeding Site Within 3 Minutes — 80.7; 50.0; 87.5; 44.4 percentage of participants — p=<0.001
Phase 3 N=102 The EVARREST® Fibrin Sealant Patch Liver Study
Hemorrhage
Primary: Hemostasis at the Target Bleeding Site (TBS) at 4-minutes Following Randomization — 48; 24 participants with hemostatic success — p=<.0001
N/A N=1,439 Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery
Surgery · Blood Loss
Primary: Unanticipated Bleeding — 0; 100; 0 percentage of participants
N/A N=20 Effect of Intermittent Pedicle Clamping on Hepatocellular Injury During Liver Surgery
Hepatocellular Injury · Blood Loss
Primary: Hepatocellular Damage Reflected by Liver Fatty-acid Binding Protein (L-FABP) Levels — 9097; 11,688 ng*h/mL
Phase 2 N=33 A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery
Hemostasis · General Surgery
Primary: To Evaluate the Safety of sFilm-FS Versus an Active-comparator (TACHOSIL®) When Used as Adjunct to Conventional Hemostatic Techniques During Elective Surgery Through…
N/A N=47 Clinical Safety and Performance of GATT-Patch in Open Liver Surgery
Hemorrhage, Surgical
Primary: Hemostasis — 38; 46 Participants
N/A N=50 Comparison of the Hemostatic Patch to Fibrin Sealant (TachoSil®) in Subjects Undergoing Hepatic Surgery
Liver Disease
Primary: Median Time to Achieve Hemostasis Following Application of Study Treatment. — 1; 3 Minutes — p=<0.0001
N/A N=25 Postoperative Heme Oxygenase Induction and Carbon Monoxide Production as a Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy
Liver Cancer
Primary: CO Output (Ppm) — 2.03 ppm
Phase 3 N=86 Usefulness of BiClamp Forceps for Liver Resection: A Randomized Clinical Trial
Hepatobiliary Disease
Primary: The Total Blood Loss — 376.73; 339.81 ml
N/A N=68 Comparison of Blood Product Use and Bleeding Events During and After Endoscopic or Neurosurgical Procedures in Patients With Cirrhosis and Coagulopathy
Cirrhosis · Coagulopathy
Primary: Intra-operative Blood Loss — 2000; 3000 milliliters
Phase 3 N=35 The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study
Controlling Mild to Moderate Bleeding During Surgery
Primary: Absolute Time to Hemostasis — 4.00 Minutes
N/A N=339 Risk Factors for Rebleeding in Patients With Obscure Gastrointestinal Bleeding
Gastrointestinal Bleeding
Primary: Rebleeding Rate — 97 participants
N/A N=60 A New Approach for Controlling Hemostasis During Canal Treatment
Blood Contamination of Root Canal During Endodontic Therapy
Primary: Change From Baseline in Root Canal Bleeding — 3.40; 3.73; 0.26; 3.03 millimeters — p=<.0001
Phase 2 N=52 Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy
Pancreas Cancer · Pancreas Disease · Pancreas Adenocarcinoma
Primary: Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF) — 13 Participants
Phase 3 N=40 The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study
Hemorrhage · Soft Tissue Bleeding · Hepatic Parenchyma Bleeding
Primary: Absolute Time to Haemostasis (TTH) — 4.0; 4.0 Minutes
Phase 4 N=150 EVARREST™ Fibrin Sealant Patch Post-Market Study
Hemorrhage · Soft Tissue Bleeding
Primary: Safety Parameter - Incidence of Thromboembolic Events — 2; 7 Participants
Phase 3 N=721 A Study of Fibrocaps™ in Surgical Bleeding
Mild or Moderate Surgical Bleeding
Primary: Time to Hemostasis (TTH) for Participants Receiving Spinal Surgery — 1.0; 2.5 minutes — p=< 0.0001
Phase 4 N=174 Preoperative High Dose Steroids for Liver Resection- Effect on Complications in the Immediate Postoperative Period
Complication, Postoperative
Primary: Complications, Post-anesthesia Care Unit (PACU) — 51; 58 Participants — p=0.213
Phase 2 N=18 Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection
Large Polyps in the Gastrointestinal Tract
Primary: Duration of the Submucosal Cushion
N/A N=57 Regeneration of Liver: Portal Vein Embolization Versus Radiofrequency Assisted Ligation for Liver Hypertrophy (REBIRTH)
Liver Resection · Cancer
Primary: Changes in Liver Remnant Volume — 18.4; 80.7 percentage change
N/A N=68 Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection
Liver Transection During Laparoscopic Liver Resection
Primary: Intraoperative Blood Loss — 195; 218 ml
N/A N=928 Safety of Endoscopic Resection of Large Colorectal Polyps: A Randomized Trial.
Colon Polyps
Primary: Number of Participants With Delayed Bleeding Complications — 16; 33 Participants
N/A N=103 SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
Hemorrhage
Primary: Haemostatic Success at 5 Minutes — 90 Participants
Phase 2 N=49 Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer
Colorectal Cancer · Metastatic Cancer
Primary: 2 Year Disease-free Survival . — 9 percentage of participants
Phase 2 N=295 Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery
Venous Thromboembolism · Deep Venous Thrombosis · Pulmonary Embolus
Primary: Avoidance of Under-anticoagulation (Peak aFXa <0.2 IU/mL) — 76.6; 79.9 percentage of participants
Phase 3 N=135 Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection
Liver Cancer
Primary: Postoperative Complications — 42; 45; 24; 24 Participants
Phase 4 N=166 Local Anesthesia Versus Saline Serum in Surgical Incision of Colorectal or Hepatic Surgery
Postoperative Pain · Surgery · Postoperative Complications
Primary: Mg of Morphine Consumption During 48 Hours Administered by Patient Controlled Analgesia System — 23; 52; 24.63; 26.78 mg
Phase 1 N=27 HEMOBLAST Pilot Clinical Investigation
Hemostasis
Primary: Mean Paired Kappa Statistic for the Assignment of SBSS Scores by 2 Investigators — 0.7754 Kappa statistic